Joined Endogenex's oversubscribed $88M Series C to complete its pivotal ReCET clinical study in type 2 diabetes.
MAR 25, 2026
Endogenex is a clinical-stage company focused on revolutionizing treatment options for individuals with type 2 diabetes (T2D) through innovative technologies that reset the body's metabolic signaling system
Endogenex is a clinical-stage company focused on revolutionizing treatment options for individuals with type 2 diabetes (T2D) through innovative technologies that reset the body's metabolic signaling system.